A Case of a Young Girl with Myelodysplastic Syndrome (MDS), Dysmorphic Features, Short Stature, and Developmental Delay – Is there a Link?

Torrey M Parker1,4, Mylene Bassal1,2,4, Robert Klaassen1,2,4, Sarah M Nikkel1,2,4, Michaela Cada1,2,4 and Donna L Johnston1,2,4*

1Department of Pediatrics, Children’s Hospital of Eastern Ontario, Canada
2Division of Hematology Oncology, University of Ottawa, Ottawa, Ontario, Canada
3Department of Medical Genetics, University of Ottawa, Ottawa, Ontario, Canada
4University of Ottawa, Ottawa, Ontario, Canada

Abstract

Myelodysplastic Syndrome (MDS) is a problem of ineffective hematopoiesis, due to a clonal disorder of the hematopoietic stem cells. MDS is rare in children and considered premalignant as it often progresses to leukemia over time. There are known inherited predisposing conditions to MDS that have been reported in the literature. We describe the case of a 12-year-old girl with multiple dysmorphic features, short stature, and developmental delay with a new diagnosis of MDS (RAEB) with no confirmed genetic diagnosis linking all these features together. We propose that her underlying syndromic diagnosis may have predisposed her to MDS.

Keywords: MDS; Genetic syndrome

Introduction

Myelodysplastic Syndrome (MDS) is a clonal disorder of hematopoiesis that frequently progresses to leukemia. MDS is rare in children and more commonly seen in adults. Many children with MDS have associated abnormalities such as pre-existing bone marrow failure, congenital abnormalities, or inherited bone marrow failure syndromes, which predispose them to the development of Acute Myeloid Leukemia (AML) and other cancers. Children with primary MDS may have underlying predisposing genetic defects; however, available evidence is limited and derived mainly from small studies and case reports [1]. We describe a case of a 12-year-old girl with an unknown syndrome, short stature, multiple dysmorphic features, and developmental delay all of which may be related to her developing MDS (RAEB).

Case Report

A 12-year-old girl with an undiagnosed syndrome presented to our hospital with a 6-month history of decreased energy, appetite and oral intake with a 3-kilogram weight loss. She also had a one-week history of intermittent non-bilious emesis and tactile temperature. She had three episodes of mild epistaxis. Her review of systems was otherwise unremarkable. She was born at 32+3 weeks to a gravida one healthy mother, with a birth weight of 1410 g. Her head ultrasound at birth showed non-unremarkable. She was born at 32+3 weeks to a gravida one healthy mother. Her chromosome microarray analysis was unremarkable. With age, her constellation of features progressed to include: short stature (minus four standard deviations), wooly hair, sensitive skin, and learning difficulties. She had delayed gross and fine motor skills. She had normal speech and intellectual capacity, but problems with information processing.

At her presentation at age 12, in addition to her aforementioned dysmorphic features and physical findings, she had an enlarged liver at 2 cm below the costal margin but no splenomegaly. Her cardiovascular and respiratory exams were unremarkable. Her White Blood Cell count (WBC) 5.74 x 109 cells/L, absolute neutrophil count 4.11 x 109 cells/L, platelets 57 x109 cells/L; hemoglobin 84 g/L; MCV 94.9 fl; reticulocytes 64 x109 cells/L. Her LDH was 1131 U/L; uric acid 117 umol/L; and ESR 70 mm/hr. Her peripheral blood smear showed 4% blasts. She had a structurally normal heart with a pericardial effusion (with no blasts) that required drainage by day 7 of hospitalization.

Her initial bone marrow aspirate demonstrated 15% blasts. Bone marrow immunophenotyping revealed that 38% of cells were an abnormal population showing variable expression of CD10, CD13, CD15, CD33, CD36, HLA-DR, CD41, CD61 and MPO, and negative for CD34, CD19, and surface CD3. These findings were suggestive of Myelodysplastic Syndrome (MDS) with excess blasts but could not exclude progression to acute myeloid leukemia (AML). Bone marrow biopsy was consistent with MDS showing a hyper cellular marrow and a typical localization of immature precursors. Bone marrow karyotype confirmed 46,XX. Fluorescent in situ Hybridization (FISH) revealed no evidence of monosomy 5 or 7, or BCR/ABL. Her chromosome breakage studies, genetic testing of exon 2 of the SBDS gene and telomere length was normal. The final diagnosis was MDS with refractory anemia with excess blasts (RAEB).

Keywords: MDS; Genetic syndrome

*Corresponding authors: Donna L Johnston, Division of Hematology-Oncology, Children’s Hospital of Eastern Ontario (CHEO), 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada, Tel: 613-737-7600 ext 2210; Fax: 613 738-4828; E-mail: djohnston@cheo.on.ca

Received March 29, 2012; Accepted April 18, 2012; Published April 28, 2012


Copyright: © 2012 Parker TM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
She was given one dose of intrathecal cytarabine at the time of her bone marrow. She was then treated with 2 cycles of azacytidine at a dose of 75 mg/m²/day for 7 days every 21 days. The second bone marrow aspirate and biopsy done following the two cycles of azacytidine were again consistent with RAEB with 8% excess myeloid blasts and megakaryocytic dysplasia. As she had only mild improvement with azacytidine therapy, she underwent a 6/6 HLA matched unrelated donor umbilical cord stem cell transplantation. She was conditioned with targeted intravenous busulfan for 4 days, cyclophosphamide 50 mg/kg/day for 4 days, and Anti Thymocyte Globulin (ATG) 2.5 mg/kg daily for 3 days, which was well tolerated.

Discussion

MDS in children is a rare and more common in adults. The morphologic, cytogenetic and genetic abnormalities, and how these lead to childhood MDS are poorly understood. Allogeneic hematopoietic stem cell transplantation (HSCT) is often the only option with a realistic chance to cure [1]. It is often difficult to predict how children will tolerate this therapy, especially if they have other congenital anomalies, pre-existing organ dysfunction or decreased ability to tolerate toxic therapy, as seen in children with Fanconi anemia and dyskeratosis congenita. Those children with inherited bone marrow failure syndromes and even those with unclassifiable bone marrow failure syndromes may have a predisposition for other malignancies, the risk of which is not eliminated by HSCT [2].

Published series of childhood MDS estimate that 30% of the patients have associated genetic syndromes [3-7], however, an exact association is difficult to know due to the possibility of under diagnosis [4-6]. The pathophysiology of childhood MDS and its association with chromosomal and genetic abnormalities are not well understood and may reflect unique biological factors that may contribute to dyshaematopoiesis [6,7].

There are known predisposing conditions to MDS that have been reported in the literature including: Down syndrome, Kostmann syndrome, Noonan syndrome [4], Fanconi anemia, Dyskeratosis congenita, Trisomy 18, Neurofibromatosis type 1, Shwachman-Diamond syndrome, and familial leukemia syndromes [1,7,8]. There has been case reports of MDS that may be associated with Naxos disease [7], Dandy-Walker syndrome, Lowe syndrome [7], and Wolf-Hirschhorn syndrome [9]. MDS associated with Down syndrome and Noonan syndrome has a more favourable prognosis and may require only supportive care. MDS associated with Fanconi anemia often requires bone marrow transplant and can have a poor prognosis [6].

Our case describes a young girl with multiple dysmorphic features, short stature, and developmental delay with a recent diagnosis of MDS (RAEB) with no confirmed genetic diagnosis linking all these features. This could be considered as an unclassifiable inherited bone marrow failure syndrome, which is associated with multineuropathy congenita with physical malformations [2]. It is difficult to know whether there is an underlying genetic abnormality that may be responsible for the progression to MDS or merely a coincidence as has been suggested by Sharathkumar [9]. Interestingly, Passmore [4] described a small number of patients with MDS with an undiagnosed genetic syndrome with associated abnormalities including: short stature, microcephaly, developmental delay, xanthomata, and xanthogranulomata. There is growing evidence that there are patients with as of yet unclassified inherited bone marrow failure syndromes, which predispose them to MDS/AML or other malignancies [2].

Future research is needed to recognize the underlying process involved in childhood MDS and to understand whether there is in fact a link to certain genetic conditions. It is plausible that underlying genetic abnormalities may have a significant impact on management. It is beneficial for clinicians to be aware that certain genetic abnormalities/ syndromes may be associated with childhood MDS in order to aid in early detection, which in turn may have an impact on overall survival.

References